Abstract
Cell-sheet transplantation induces angiogenesis for chronic myocardial infarction (MI), though insufficient capillary maturation and paucity of arteriogenesis may limit its therapeutic effects. Omentum has been used clinically to promote revascularization and healing of ischemic tissues. We hypothesized that cell-sheet transplantation covered with an omentum-flap would effectively establish mature blood vessels and improve coronary microcirculation physiology, enhancing the therapeutic effects of cell-sheet therapy. Rats were divided into four groups after coronary ligation; skeletal myoblast cell-sheet plus omentum-flap (combined), cell-sheet only, omentum-flap only, and sham operation. At 4 weeks after the treatment, the combined group showed attenuated cardiac hypertrophy and fibrosis, and a greater amount of functionally (CD31+/lectin+) and structurally (CD31+/α-SMA+) mature blood vessels, along with myocardial upregulation of relevant genes. Synchrotron-based microangiography revealed that the combined procedure increased vascularization in resistance arterial vessels with better dilatory responses to endothelium-dependent agents. Serial 13N-ammonia PET showed better global coronary flow reserve in the combined group, mainly attributed to improvement in the basal left ventricle. Consequently, the combined group had sustained improvements in cardiac function parameters and better functional capacity. Cell-sheet transplantation with an omentum-flap better promoted arteriogenesis and improved coronary microcirculation physiology in ischemic myocardium, leading to potent functional recovery in the failing heart.
Introduction
Heart failure following myocardial infarction (MI) is a major cause of death and disability worldwide. Despite advances in drug and device therapy, recovery of cardiac function and prevention of transition to heart failure in MI patients remain unsatisfactory, indicating the need for development of novel therapeutic alternatives.1 Myocardial regenerative therapy with cell-sheet transplantation has been shown to induce angiogenesis via paracrine effects in a chronic MI model.2,3 However, the proangiogenic effect of the stand-alone cell-sheet treatment may be insufficient to fully relief ischemia in the chronic MI heart that involves a large territory of the left ventricle (LV), since the coronary inflow of the ischemic/infarct myocardium is dependent upon collateral arteries from other territories.4,5 In addition, microvascular dysfunction is present in critical chronic MI heart across a wide range of the peripheral coronary tree.6 This highlights the need for a comprehensive understanding of the mechanism of angiogenesis induced by a cell-sheet therapy in ischemic hearts.
For successful therapeutic neovascularization of ischemic tissues, it is essential to induce robust angiogenic responses (angiogenesis), and establish functionally and structurally mature arterial vascular networks (arteriogenesis) that show long-term stability and control perfusion.5 Establishment of mature vessels is a complex process that requires several angiogenic factors to stimulate vessel sprouting and remodeling (endothelial tubulogenesis accompanied with a pericyte recruitment) of the primitive vascular network. Endothelial vasodilator function of coronary microvessels (resistance arterial vessels) is also an important determinant of myocardial perfusion in response to increased myocardial oxygen demand, playing a critical role in neovascular therapies.6,7,8 The attenuated therapeutic effects observed in the previous clinical trials were caused by multiple factors including generation of unstable blood vessels that regress over time or functionally immature vessels accompanied with endothelial dysfunction in ischemic areas.5,9
The omentum (OM), historically used in surgical revascularization for patients with ischemic heart disease, is also known to release a number of angiogenic cytokines and attenuate inflammation.10,11,12,13,14 In addition, the gastroepiploic artery involved in the OM-flap can play an important role as an extracardiac blood source with high perfusion capacity for developing effective collateral vessels for advanced coronary artery disease. We established a combination strategy of cell-sheet transplantation covered with a pedicle OM-flap in porcine models, allowing us to implant large numbers of cells and improve cell survival.13,14 However, data are scarce regarding the therapeutic effects of such combined treatment on vessel maturity and coronary microcirculation physiology in ischemic territory. We hypothesized that cell-sheet transplantation with a pedicle OM-flap will better promote arteriogenesis and stabilize blood vessels in ischemic myocardium along with improved coronary microcirculation physiology, consequently enhancing the therapeutic effects of cell-sheet therapy. Herein, we focused on vessel maturation induced by cell-sheet therapy with an OM-flap and evaluated the physiological benefits in coronary microcirculation utilizing modern modalities such as in vivo synchrotron-based microangiography and positron emission tomography (PET).
Results
Histological analysis of host myocardium
Four weeks after treatment, myocardial structural components, collagen accumulation and cardiomyocyte hypertrophy, were assessed by hematoxylin-eosin, Masson trichrome, and Periodic acid-Schiff staining (n = 11 for each group). LV myocardial structure was better maintained in the combined group as compared with the others (Figure 1c). The combined group had a significantly thickened anterior LV wall (anterior wall thickness, control 392 ± 31 versus combined 912 ± 34 versus sheet-only 688 ± 27 versus OM-only 500 ± 28 μm) (Figure 1d). That group also had a significantly attenuated collagen accumulation (percent fibrosis, 18 ± 1 versus 8 ± 4 versus 13 ± 6 versus 14 ± 1%, respectively) (Figure 1e) and cardiac hypertrophy (myocyte size, 23 ± 1 versus 16 ± 1 versus 20 ± 3 versus 21 ± 2 μm, respectively) (Figure 1f) in the peri-infarct regions (ANOVA P < 0.001 for all).
Gene expressions in peri-infarct myocardium during acute treatment phase
The myocardial gene expressions related to angiogenesis, vessel maturation, and anti-inflammation were analyzed at 3 days after each treatment using real-time PCR (n = 6 for each group). As compared to the others, the combined group showed substantially higher gene expressions of vascular endothelial growth factor (VEGF)-A, VEGF receptor-1, VEGF receptor-2, Akt-1, platelet-derived growth factor (PDGF)-β, angiopoietin (Ang)-1, Tie-2, vascular endothelial (VE)-cadherin, platelet endothelial cell adhesion molecule (PECAM)-1, and stromal cell-derived factor (SDF)-1 in peri-infarct myocardium at the early stage of transplantation (Figure 2).
Vessel recruitment in transplanted cell-sheets and donor cell survial
To evaluate the effect of adding OM-flap to the cell-sheet therapy on the vessel recruitment (angiogenesis) in the transplanted area that should be related to the donor cell survival, we serially assessed the number of functional blood vessels with patent endothelial layers (CD31/lectin double-positive cells) in the transplanted area of the sheet-only and combined groups at 3, 7, and 28 days after each treatment (n = 6 for each group and each time point) (Figure 3a–f). At 3 days after treatment, in the sheet-only group, several blood vessels were just located at the border between the sheet and infarct area (Figure 3a), whereas a large number of functional vessels was detected proximal to the border between the cell-sheet and OM and within the sheet in the combined group (Figure 3d), suggesting that the cell-sheet received blood supply directly from the infarct myocardium and OM. Consequently, the combined group had greater numbers of functional blood vessels in the cell-sheet than the sheet-only group at any follow-up point, although both groups showed steady decrease in the number of vessels during the 28 days (Figure 3g).
The quantitative assessments of the donor (GFP-positive) cell presence were also serially performed to elucidate the donor cell dynamics in the sheet-only (Figure 3a–c) and combined (Figure 3d–f) groups. We traced the transplanted donor cells and found that there was no significant difference in the engrafted area at 3 days after transplantation between the groups, while the subsequent changes in each group were apparently distinctive (Figure 3h). During the 7days after the treatment, the amount of decrease in the engrafted area was substantially smaller in the combined group than that in the sheet-only group, resulting in 4.3-fold increased retention of donor cells in the former group. This led to the greater donor cell presence in the combined group persistently (at least until day 28), which was consistent with the amount of vessel recruitment in the cell-sheet.
Vessel remodeling and maturation in peri-infarct myocardium
We serially assessed neovascular vessel maturity in peri-infarct areas at 3 (n = 6 for each group) and 28 days (n = 11 for each group) after treatment (Figure 4). Vessel density and structural maturity were quantified as the number of CD31 positive and CD31/α-smooth muscle actin (SMA) double-positive vessels per mm2, respectively. A maturation index was calculated as the percentage of CD31/α-SMA double-positive vessels to total vessel number. Functionally mature vessels with patent endothelial layers were assessed by lectin injection, which binds uniformly and rapidly to the luminal surface of endothelium, thus labeling patent blood vessels. Vessels positive for CD31 but negative for lectin were regarded as functionally immature and undergoing regression, or that had lost patency.15,16
In general, α-SMA signals were located at the outer edges of CD31 staining, indicating pericyte attachment to newly formed endothelium. Three days after treatment, there was no difference in number of CD31-positive cells among the groups, though the combined group showed a trend of greater number of functional blood vessels with patent endothelial layers (CD31/lectin double-positive) and structurally (CD31/α-SMA double-positive) mature vessels, with a higher maturation index (Figure 4a–g). Notably, the percentage without lectin staining (CD31+/lectin-) was significantly smaller in the combined group.
The number of endothelial (CD31 positive) cells in the control and single treatment groups decreased with time, while that in the combined remained unchanged. Consequently, the angiogenic effects induced in the latter were more profound at 28 days after treatment, with a significantly greater amount of mature vessels (Figure 4h–n).
Number of resistance vessels and relative dilatory responses to endothelium-dependent stimulation in ischemic myocardium
To evaluate the effects of each treatment on microcirculation physiology in terms of relative dilatory responses to acetylcholine and dobutamine hydrochloride in the resistance vessels, synchrotron radiation microangiography was performed after 3 weeks after the treatment (control: n = 11, combined: n = 11, cell-sheet: n = 5, OM: n = 6). Using iodinated agents, coronary microcirculation in ischemic areas was clearly visualized in anesthetized closed-chest rats (Figure 5a). Vessel internal diameter (ID) at baseline (before agent administration) tended to decrease according to branching order and differed among the groups with larger first branching order arteries observed in the combined group (Figure 5b). Moreover, the combined group had a greater number of third and fourth branching order arterial vessels (resistance arterial vessels) at baseline (Figure 5c).
Acetylcholine-mediated dilation in the third and fourth branching orders was significantly different among the groups. The mean caliber changes in response to acetylcholine in the combined group were 28 ± 8% and 32 ± 8% for the third and fourth order branches respectively, which were greater than in the others (Figure 5d). Similarly, the mean caliber changes in response to dobutamine hydrochloride in the combined group were 31 ± 7% and 34 ± 7%, respectively, which were greater than in the others (Figure 5e).
The distributions of individual segment caliber changes in response to acetylcholine are described in Supplementary Figure S1. The control group had a relatively high frequency of third and fourth branching order arterial vessels showing localized segmental vasoconstriction (ID constriction >5% of baseline). The frequency of abnormal vasoconstriction with acetylcholine in the control group was about eight- and fourfold for the third and fourth branching order, respectively, as compared with the combined group (third order: control 49% versus combined 6% versus sheet-only 22% versus OM-only 25%; fourth order: control 18% versus combined 4% versus sheet-only 13% versus OM-only 17%).
Global and regional changes in myocardial blood flow and coronary flow reserve
To evaluate global and regional myocardial blood flow (MBF), and coronary flow reserve (CFR), 13N-ammonia PET measurements were serially performed 1 day before and 3 weeks after the treatments (control: n = 5, combined: n = 8, cell-sheet: n = 7, OM: n = 7) (Figure 6a–f). In normal rats used for the validation study, global MBF at rest and during stress was 5.1 ± 0.5 and 7.1 ± 1.3 ml/min/g respectively, while global CFR was 1.4 ± 0.3.
Two weeks after coronary ligation (before treatment), global MBF at rest and during stress were substantially decreased in all groups, with no significant differences. Similarly, global CFR was not different among the groups. Three weeks after treatment, global MBF at rest was not different, while that during stress was significantly greater in the combined and single treatment groups as compared to the control (control 2.5 ± 0.4 versus combined 3.8 ± 0.6 versus sheet-only 3.3 ± 0.5 versus OM-only 3.8 ± 0.3, respectively, ANOVA p=0.0003). Postoperative global CFR was also substantially higher in the treatment groups as compared with the control (control 1.1 ± 0.2 versus combined 1.4 ± 0.2 versus sheet-only 1.4 ± 0.2 versus OM-only 1.4 ± 0.2, respectively, ANOVA p=0.015).
With regard to the magnitude of change in the global CFR (pre- versus post-treatment), the combined group offered the most remarkable improvement in the global CFR, as evidenced by a higher ratio of post- to pre-treatment CFR. Notably, that beneficial change was mainly caused by significant improvement in the basal left ventricle (control 0.9 ± 0.1 versus combined 1.4 ± 0.4 versus sheet-only 1.0 ± 0.1 versus OM-only 1.1 ± 0.1, respectively, ANOVA P = 0.012) (Figure 6e,f).
Global LV function and hemodynamic performance
The cardiac function was evaluated by echocardiography before (at baseline) and 2 and 4 weeks after each treatment (n = 11 for each group) (Figure 6 g,h). Two weeks after left coronary artery ligation, severe dilatation of the LV chamber and severe systolic dysfunction were observed, with no significant differences among the groups (Figure 6g). In the control, LV dimensions increased and LV ejection fraction deteriorated in a time-dependent manner, suggesting progressive LV remodeling. In the sheet-only and OM-only groups, LV ejection fraction initially improved, then tended to deteriorate in association with gradual LV dilatation. In the combined group, remarkable improvements in LV function parameters occurred promptly and were sustained for up to 4 weeks, resulting in significantly smaller LV dimensions and greater LV ejection fraction as compared with other treatment groups.
Consistently, the basic hemodynamic indices revealed that LV end-systolic pressure was higher, whereas LV end-diastolic pressure and time constant were lower in the combined group as compared to the others. Load-independent parameters assessed by pressure–volume loop analysis revealed that end-systolic pressure–volume relationship was higher, while end-diastolic pressure–volume relationship was lower in the combined group (Figure 6h). These results confirmed that cell-sheet therapy combined with OM-flap improved the therapeutic effects of single treatment group (cell-sheet only or OM-flap only) for the treatment of chronic MI.
Functional capacity assessment
There was no difference in running distance at 4 rpm (control 125 ± 15 versus combined 148 ± 9 versus sheet-only 133 ± 10 versus OM-only 135 ± 15 m, ANOVA P = 0.63) (n = 11 in each). In contrast, the combined group showed more improved functional capacity in terms of longer running distance at 8 rpm (54 ± 5 versus 178 ± 17 versus 81 ± 10 versus 76 ± 7 m, respectively, ANOVA P < 0.001).
Angiographic assessment of communication between coronary arteries and pedicle omentum
Communication between the coronary arteries and branches of the gastroepiploic artery in the OM specimens was evaluated using three different methods with a different series of OM-only and combined group animals (n = 12 in each) (Figure 1a).
A postmortem angiography examination from the aortic root was performed to verify antegrade flow from the OM into the heart in the combined and OM-only groups (n = 4 for each group). In the combined group, aortography revealed that the gastroepiploic artery branches feeding the OM expanded into the heart, and established several tight junctions between the native coronary arteries and OM (Figure 7a). In contrast, in the OM-only group, the gastroepiploic artery branches failed to penetrate the heart, accompanied by immature leaky collateral vessel formation between the coronary artery and OM, evidenced by considerable leakage of contrast agent (Figure 7b).
We selectively injected India ink into the celiac artery to visually and histologically confirm vessel communication between the pedicle OM and native coronary artery (n = 4 for each group). Numerous collaterals filled with India ink were clearly identified between the gastroepiploic artery and native coronary arteries in the combined group, while that was not seen in the OM-only group (data not shown) (Figure 7c–e). Histological analysis confirmed vessel communication between those in the combined group (Figure 7f,g).
Finally, a selective perfusion via aortic root and celiac artery using two different MICROFIL colors was performed (n = 4 for each group). In the combined group, MICROFIL solution injected in a retrograde manner into the aortic root (MV-117 Orange) was easily shown expanded into the OM to communicate with the gastroepiploic artery (Figure 7h). That solution injected into the celiac artery (MV-120 Blue) was also found to expand into the myocardium and communicated with native coronary arteries (Figure 7i). Those findings were not seen in the OM-only group (data not shown).
Vessel migration into cell-sheet from host myocardium and omentum
To further confirm whether the OM- and host myocardium-derived endothelial cells migrated toward the cell-sheet, we established two types of parabiotic pair models (n = 4 for each).
In parabiotic pairs of wild-type MI rats that received transplantation of cell-sheets labeled with Cell Tracker TM Orange CMTMR followed by coverage with a GFP-transgenic rat oriented pedicle OM, a large number of OM-derived endothelial cells (isolectin/GFP double-positive cells) had migrated toward the cell-sheet (Figure 8a–d). Similarly, in another parabiotic pair of GFP-transgenic MI rats that received cell-sheet transplantation covered with a wild-type rat oriented pedicle OM, a large number of host myocardium-derived endothelial cells (isolectin/GFP double-positive cells) had migrated toward the cell-sheet (Figure 8e–h).
Cell-sheet stimulated vascular cell migration
We performed an in vitro migration assay using HUVECs to evaluate the effects of skeletal myoblast cell-sheet derived growth factors on vessel recruitment (Figure 8i). The number of migrating cells was significantly greater in the 100% conditioned medium group, followed by the 10% conditioned medium and control groups, suggesting that SM cell-sheet derived growth factors stimulate vascular cell migration in a concentration-dependent manner (Figure 8j,k).
Discussion
The major findings of this study can be summarized as follows. As compared to the single treatment groups, the cell-sheet plus OM group showed (i) improved donor cell retention along with amplified angiogenesis in the cell-sheet through the follow-up (at least day 28), (ii) attenuated cardiac hypertrophy and fibrosis, and a greater amount of functionally and structurally mature blood vessels in the ischemic myocardium, along with myocardial upregulation of relevant genes, (iii) increased vascularization in resistance arterial vessels with better dilatory responses to endothelium-dependent agents, (iv) more remarkable improvement in the global CFR, mainly caused by significant improvement in the basal left ventricle, (v) sustained improvements in cardiac function parameters and better functional capacity, and (vi) creation of robust vascular communication between the OM and native coronary arteries, shown by in vivo angiography.
The retention, survival, and engraftment of transplanted cells in the cell-sheet therapy are largely influenced by the degree of vascularization in the transplanted area and subsequent myocardial inflammation after cell-sheet transplantation.2,17 The concept of combining OM-flap with the current cell-sheet therapy is likely to be reasonable because the OM is known to play a key role in controlling the spread of inflammation, and promoting revascularization, reconstruction and tissue regeneration. Our data suggest that the combined treatment improved the hypoxic environment in the transplanted area to a greater degree, potentially improving initial cell engraftment and enhancing the paracrine effects induced by cell-sheet therapy in terms of higher expressions of relevant genes, subsequently stabilizing therapeutic effect of cell-sheet therapy. The discrepancy between functional improvement and donor cell engraftment suggests that the improvement of cardiac function is not mainly mediated by direct contribution of transplanted donor cells but other indirect roles, possibly paracrine effects, offered by the cell-sheet at the early stage of transplantation.
The histological findings demonstrated that the rats receiving the cell-sheet implantation plus OM-flap had a significantly thickened anterior LV wall that was augmented by cardiomyocyte layers as compare to the other groups. Potential mechanisms may include cardiomyogenic differentiation of the donor-derived cells or endogenous stem cells, or paracrinal inhibition of progressive necrosis and/or apoptosis of the native cardiomyocytes. We speculate that both mechanisms might have contributed to the thickening of the targeted LV wall, although cardiomyogenic differentiation was not clearly identified in this study. Improved regional blood flow by the combined therapy could reduce the number of the necrotic/apoptotic cardiomyocytes, while reduced accumulation of fibrous components would inhibit thinning of the LV wall.5,18 In addition, girdling effects from the covered OM might have reduced wall stress of the LV, leading to maintenance of the LV thickness.19 Further studies to focus on the cardiomyogenic transdifferentiation using genetically labeled rodent models are warranted.
When blood vessels grow, endothelial cells migrate out first and assemble in a primitive network of immature channels (angiogenesis).5 As these nascent vessels only consist of endothelial cells, they rupture easily and are leaky, prone to regression, and poorly perfused.18,20,21,22 Recruitment of mural cells around nascent vessels essentially contributes to remodeling and maturation of the primitive vascular network (arteriogenesis), subsequently causing therapeutic improvement of blood perfusion.5,18 We found a larger percentage of vessels without lectin staining and lower maturation index in the control and single treatment groups, indicating that promotion of angiogenesis, but failure to effectively induce arteriogenesis. Consequently, the single treatments showed only transient effects on global cardiac function and limited functional capacity, possibly due to irregular capillary networks and increased vascular permeability. In the combined treatment group, greater numbers of functionally and structurally mature vessels were established promptly after treatment and maintained in ischemic myocardium. This might be primarily attributed to upregulated expressions of genes related to angiogenesis (VEGF, VEGFR-1, VEGF-R2, Akt-1) and/or endogenous regeneration (SDF-1). Moreover, elevated expressions of Ang-1 and its receptor Tie-2, and PDGF, VE-cadherin, and PECAM might play key roles in promoting maturation processes such as “stabilization” of cell junctions and tight pericyte recruitment (arteriogenesis).5,15,16,18,20,21,22 Interestingly, the elevated expression of the those relevant genes shown in the combined group was mostly reduced after 28 days after treatment (data not shown), corresponding with reduced donor cell presence. We found, however, the combined treatment group showed more sustained positive effects on vessel maturity and cardiac function recovery as compared with the control and single treatment groups at 28 days after treatment, indicating that paracrine mediators contribute to the myocardial recovery mainly during the early phase after the treatment and the effects on cardiac function and vessel structure, once established, could last for a longer time.2 These data suggest that OM-flap covering the cell-sheet played a key role in accomplishing the maturity of the new vessels in the targeted myocardial territory, leading to formation of more organized and durable vascular network, as compared to the control and the single treatment groups.
Endothelial vasodilator function of coronary microvessels (resistance arterial vessels) is an important determinant of myocardial perfusion in response to increased myocardial oxygen demand, playing a critical role in neovascular therapies.6,7,8 Vasodilation in response to specific endothelium-dependent and endothelium-independent stimuli within the coronary circulations can be measured to assess endothelial function. To the best of our knowledge, this is the first to verify that cell-sheet treatment with and without OM-flap could improve endothelial vasodilator function of resistance arterial vessels in a rat MI model, utilizing in vivo synchrotron-based microangiography that has proved an effective method for clearly visualizing resistance arterioles and accurately identifying neurohumoral modulation of coronary blood flow within the microcirculation for assessing therapy efficacy.7,23,24 Microangiography revealed attenuated dilatation and a strong trend toward increased incidence of paradoxical constrictions in the control, followed by the single treatment group, suggesting that the endothelial-dependent vasodilator function in resistance arterial vessels was progressively impaired in those groups.25,26 In contrast, combined treatment effectively restored endothelial function in resistance arterial vessels, evidenced by better dilatory responses to acetylcholine, an endothelium-dependent vasodilator.27 This corresponds with PET/CT findings demonstrating substantial improvement in CFR, which indicated the ability of the myocardium to increase blood flow in response to increasing myocardial oxygen demand. Adenosine causes vasodilation by stimulating receptors in the microcirculation, facilitating measurement of the endothelium-independent CFR in the microcirculation. Interestingly, a remarkable improvement in CFR was observed in basal, but not apical LV, indicating that the combined treatment might be capable of improving microvasculature functionality of hibernating myocardium, rather than scar cardiac tissue. These physiological benefits in the coronary microcirculation may activate collateral growth through increased flow and shear stress, a powerful driving force of arteriogenesis, leading to enhanced functional capacity under a high load.28,29 Therefore, we speculate that the present combined treatment strategy has potential to effectively prevent progression of endothelial dysfunction, which independently predicts major clinical adverse events in patients with heart failure.28,29,30
Our data suggest that the combination of cell sheet transplantation and OM-flap acts synergistically, rather than additively, on vessel maturation, coronary microcirculation physiology, functional capacity, and cardiac reverse remodeling, whereas the OM-only strategy failed to stabilize its long-term effect. These results encouraged us to investigate the role of the cell-sheet transplantation in activating the effects of OM-flap. Postmortem angiography findings demonstrated visible collateral vessels between the native coronary arteries and OM-flap in the combined group, whereas no tight junctions were shown in the OM-only group, indicating that formation of collateral vessels between native coronary arteries and OM was accelerated by the interposed cell-sheets. The possible mechanism of those findings might be explained by our in vitro migration assay demonstrating that growth factors and cytokines secreted by the cell-sheet stimulate migration of endothelial cells derived from both host myocardium and the OM toward the sheet, subsequently establishing robust vessel connections with persistent blood flow between the native coronary arteries and OM. In contrast, in the OM-only group, lack of that process caused immature leaky collateral vessel formation and thus inadequate collateral blood flow in the ischemic myocardium. Based on those findings, we speculate that the therapeutic effects of the combined treatment strategy might be responsible for increased donor cell survival and stimulation of donor cells induced by OM-flap as well as for cell-sheet–mediated activation of OM-flap as a donor artery with high perfusion capacity. Nevertheless, further studies are absolutely needed to determine the main molecular mechanism of therapeutic effects induced by the combined treatment.
Limitations
Considering the potential molecular mechanisms behind the beneficial histological and physiological alterations observed with the combined strategy, we found that a group of possibly relevant molecules including VEGF-A, VEGF receptor-1, VEGF receptor-2, Akt-1, SDF-1, PDGF-β, Ang-1, Tie-2, VE-cadherin, and PECAM were upregulated in the combined group, suggesting that the effects may be attributed to activation of several paracrine molecules, rather than a single molecule. Although some may argue what kinds of cytokines play a major role in generating therapeutic effects among the many complex molecular and cellular mechanisms involved, we consider that establishment of mature vessels is a complex process that is not regulated by specific factors, but rather numerous multiple factors that also dynamically change in response to the process of angiogenesis or vessel maturation. We believe that use of a cell-sheet and pedicle-OM as synergistic intelligent engineered tissues can efficiently support the regenerative process by dynamic cross-talk with ischemic cardiac tissue.
Although we did not experience any complication such as torsion of omentum flap or diaphragmatic hernia in the rats receiving the combined treatment, it is considered that a conventional lapalotomy itself may adversely affect general conditions particularly in critically-ill heart failure patients. An endoscopic approach may be useful in minimizing the OM-flap procedure-related complications in clinical settings.
Conclusion
We demonstrated that cell-sheet transplantation with an omentum-flap better promoted arteriogenesis and improved coronary microcirculation physiology in ischemic myocardium tissue, leading to potent functional recovery in a rat MI model. Further development of this treatment strategy toward clinical application is encouraged.
Materials and Methods
All experimental procedures were approved by an institutional ethics committee. Animal care was conducted humanely in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals, prepared by the Institute of Animal Resources and published by the National Institutes of Health (publication no. 85-23, revised 1996).
Two weeks after left coronary artery ligation, rats were divided into four groups: (i) skeletal myoblast cell-sheet transplantation covered with an OM-flap (combined group), (ii) cell-sheet transplantation only, (iii) OM-flap only, and (iv) sham operation (control group). The protocol of this study is shown in Figure 1a,b. All in vivo and in vitro assessments were carried out in a blinded manner. A detailed description of all methods and reagents used for the experiments is provided in the Supplementary Materials and Methods.
SUPPLEMENTARY MATERIAL Figure S1. Frequency distribution charts showing individual segment caliber changes in response to acetylcholine in (a) third and (b) fourth branching order vessels. Materials and Methods.
Acknowledgments
We thank Tsuyoshi Ishikawa, Yuuka Fujiwara, Yuka Kataoka, Hiromi Nishinaka, Toshika Senba, and staff of the PET Molecular Imaging Center for their excellent technical assistance. This research was supported by Research on Regenerative Medicine for Clinical Application from the Ministry of Health, Labour and Welfare of Japan and the Australian Synchrotron International Synchrotron Access Program (ISAP AS-IA111). Experiments were performed at the Japan Synchrotron Radiation Research Institute (SPring-8, BL28B2, Proposal 2011A1169). T.S. is a consultant for CellSeed, Inc., and T.O. is an Advisory Board Member of CellSeed, Inc. and an inventor/developer holding a patent for temperature-responsive culture surfaces. The authors have no conflicts of interest to report.
Supplementary Material
References
- Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378:704–712. doi: 10.1016/S0140-6736(11)60894-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Narita T, Shintani Y, Ikebe C, Kaneko M, Harada N, Tshuma N.et al. (2013The use of cell-sheet technique eliminates arrhythmogenicity of skeletal myoblast-based therapy to the heart with enhanced therapeutic effects Int J Cardiol 168261–269. [DOI] [PubMed] [Google Scholar]
- Sekiya N, Matsumiya G, Miyagawa S, Saito A, Shimizu T, Okano T.et al. (2009Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart J Thorac Cardiovasc Surg 138985–993. [DOI] [PubMed] [Google Scholar]
- Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML.et al. (1991Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators Circulation 83739–746. [DOI] [PubMed] [Google Scholar]
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307. doi: 10.1038/nature10144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gutiérrez E, Flammer AJ, Lerman LO, Elízaga J, Lerman A, Fernández-Avilés F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34:3175–3181. doi: 10.1093/eurheartj/eht351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shirai M, Schwenke DO, Tsuchimochi H, Umetani K, Yagi N, Pearson JT. Synchrotron radiation imaging for advancing our understanding of cardiovascular function. Circ Res. 2013;112:209–221. doi: 10.1161/CIRCRESAHA.111.300096. [DOI] [PubMed] [Google Scholar]
- Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
- Banquet S, Gomez E, Nicol L, Edwards-Lévy F, Henry JP, Cao R.et al. (2011Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure Circulation 1241059–1069. [DOI] [PubMed] [Google Scholar]
- O'Shaugnessy L. Surgical treatment of cardiac ischemia. Lancet. 1937;232:185–194. [Google Scholar]
- Takaba K, Jiang C, Nemoto S, Saji Y, Ikeda T, Urayama S.et al. (2006A combination of omental flap and growth factor therapy induces arteriogenesis and increases myocardial perfusion in chronic myocardial ischemia: evolving concept of biologic coronary artery bypass grafting J Thorac Cardiovasc Surg 132891–899. [DOI] [PubMed] [Google Scholar]
- Shrager JB, Wain JC, Wright CD, Donahue DM, Vlahakes GJ, Moncure AC.et al. (2003Omentum is highly effective in the management of complex cardiothoracic surgical problems J Thorac Cardiovasc Surg 125526–532. [DOI] [PubMed] [Google Scholar]
- Shudo Y, Miyagawa S, Fukushima S, Saito A, Shimizu T, Okano T.et al. (2011Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model J Thorac Cardiovasc Surg 1421188–1196. [DOI] [PubMed] [Google Scholar]
- Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Ito E.et al. (2013Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart Circulation 12811 Suppl 1S87–S94. [DOI] [PubMed] [Google Scholar]
- Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T.et al. (2006Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 1162610–2621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P.et al. (2004Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am J Pathol 16535–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shimizu T, Sekine H, Yang J, Isoi Y, Yamato M, Kikuchi A.et al. (2006Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues FASEB J 20708–710. [DOI] [PubMed] [Google Scholar]
- Carmeliet P, Conway EM. Growing better blood vessels. Nat Biotechnol. 2001;19:1019–1020. doi: 10.1038/nbt1101-1019. [DOI] [PubMed] [Google Scholar]
- Hagège AA, Vilquin JT, Bruneval P, Menasché P. Regeneration of the myocardium: a new role in the treatment of ischemic heart disease. Hypertension. 2001;38:1413–1415. doi: 10.1161/hy1201.099618. [DOI] [PubMed] [Google Scholar]
- Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437:497–504. doi: 10.1038/nature03987. [DOI] [PubMed] [Google Scholar]
- Cao Y, Hong A, Schulten H, Post MJ. Update on therapeutic neovascularization. Cardiovasc Res. 2005;65:639–648. doi: 10.1016/j.cardiores.2004.11.020. [DOI] [PubMed] [Google Scholar]
- Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464–478. doi: 10.1038/nrm2183. [DOI] [PubMed] [Google Scholar]
- Jenkins MJ, Edgley AJ, Sonobe T, Umetani K, Schwenke DO, Fujii Y.et al. (2012Dynamic synchrotron imaging of diabetic rat coronary microcirculation in vivo Arterioscler Thromb Vasc Biol 32370–377. [DOI] [PubMed] [Google Scholar]
- Iwasaki H, Fukushima K, Kawamoto A, Umetani K, Oyamada A, Hayashi S.et al. (2007Synchrotron radiation coronary microangiography for morphometric and physiological evaluation of myocardial neovascularization induced by endothelial progenitor cell transplantation Arterioscler Thromb Vasc Biol 271326–1333. [DOI] [PubMed] [Google Scholar]
- Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW.et al. (1986Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries N Engl J Med 3151046–1051. [DOI] [PubMed] [Google Scholar]
- Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60:1455–1469. doi: 10.1016/j.jacc.2011.11.082. [DOI] [PubMed] [Google Scholar]
- Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168–175. doi: 10.1161/01.atv.0000051384.43104.fc. [DOI] [PubMed] [Google Scholar]
- Poelzl G, Frick M, Huegel H, Lackner B, Alber HF, Mair J.et al. (2005Chronic heart failure is associated with vascular remodeling of the brachial artery Eur J Heart Fail 743–48. [DOI] [PubMed] [Google Scholar]
- Meyer B, Mörtl D, Strecker K, Hülsmann M, Kulemann V, Neunteufl T.et al. (2005Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide J Am Coll Cardiol 461011–1018. [DOI] [PubMed] [Google Scholar]
- Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol. 2005;25:1174–1179. doi: 10.1161/01.ATV.0000166516.52477.81. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.